Origin Bio

Origin Bio is a clinical-stage biotechnology company focused on developing novel therapeutics for metabolic and immunological diseases. The company's primary research efforts are directed toward high-prevalence conditions including metabolic dysfunction-associated steatohepatitis (MASH), obesity, and type 2 diabetes. Its lead program, OB002, is a long-acting fibroblast growth factor 21 (FGF21) analog currently in clinical development for the treatment of MASH. Origin Bio utilizes a proprietary protein engineering platform to optimize the pharmacokinetic and pharmacodynamic profiles of its biologic candidates. Headquartered in Suzhou, China, the company is supported by a syndicate of leading global investors and maintains a robust pipeline of multi-agonist peptides. The leadership team brings extensive experience from global pharmaceutical companies, aiming to bridge the gap between innovative science and clinical application.